Sullivan Bruyette Speros & Blaney LLC lifted its holdings in Stryker Co. (NYSE:SYK) by 6.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,184 shares of the medical technology company’s stock after buying an additional 72 shares during the period. Sullivan Bruyette Speros & Blaney LLC’s holdings in Stryker were worth $243,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC increased its position in Stryker by 6.5% in the 4th quarter. Geode Capital Management LLC now owns 3,665,205 shares of the medical technology company’s stock valued at $573,387,000 after buying an additional 224,785 shares in the last quarter. CWM LLC increased its position in Stryker by 111.0% in the 1st quarter. CWM LLC now owns 50,193 shares of the medical technology company’s stock valued at $9,914,000 after buying an additional 26,401 shares in the last quarter. Horan Capital Advisors LLC. bought a new stake in Stryker in the 1st quarter valued at about $40,000. Suncoast Equity Management increased its position in Stryker by 0.7% in the 1st quarter. Suncoast Equity Management now owns 85,372 shares of the medical technology company’s stock valued at $16,863,000 after buying an additional 625 shares in the last quarter. Finally, Monte Financial Group LLC bought a new stake in Stryker in the 1st quarter valued at about $277,000. Hedge funds and other institutional investors own 74.14% of the company’s stock.

In other news, Director Allan C. Golston sold 3,399 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $209.84, for a total value of $713,246.16. Following the transaction, the director now owns 13,762 shares in the company, valued at approximately $2,887,818.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Timothy J. Scannell sold 4,666 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $197.68, for a total value of $922,374.88. Following the completion of the transaction, the insider now owns 155,347 shares in the company, valued at approximately $30,708,994.96. The disclosure for this sale can be found here. Insiders sold a total of 20,447 shares of company stock worth $4,262,634 in the last 90 days. Company insiders own 7.20% of the company’s stock.

A number of analysts recently commented on the company. Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, July 29th. Svb Leerink reaffirmed an “outperform” rating on shares of Stryker in a research report on Wednesday, July 10th. Credit Suisse Group boosted their target price on Stryker from $232.00 to $237.00 and gave the company an “outperform” rating in a research report on Friday, July 26th. BTIG Research reaffirmed a “buy” rating and issued a $228.00 target price on shares of Stryker in a research report on Monday, July 29th. Finally, ValuEngine raised Stryker from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Five investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Stryker has a consensus rating of “Buy” and a consensus price target of $214.89.

Shares of NYSE SYK traded up $0.97 during midday trading on Wednesday, reaching $218.91. The company’s stock had a trading volume of 174,381 shares, compared to its average volume of 1,075,709. Stryker Co. has a 12-month low of $144.75 and a 12-month high of $222.59. The firm has a 50 day moving average price of $211.77 and a 200-day moving average price of $195.53. The stock has a market capitalization of $82.32 billion, a P/E ratio of 29.95, a PEG ratio of 2.63 and a beta of 0.85. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.07 and a quick ratio of 1.26.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 25th. The medical technology company reported $1.98 earnings per share for the quarter, topping analysts’ consensus estimates of $1.93 by $0.05. Stryker had a return on equity of 25.98% and a net margin of 24.99%. The firm had revenue of $3.65 billion for the quarter, compared to the consensus estimate of $3.60 billion. During the same quarter in the previous year, the business earned $1.76 EPS. The company’s revenue was up 9.9% compared to the same quarter last year. On average, equities analysts predict that Stryker Co. will post 8.21 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 0.95%. Stryker’s payout ratio is presently 28.45%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: How to Use the New Google Finance Tool

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.